Brookie M Best1, Miguel Goicoechea. 1. University of California, Division of Pharmacology and Drug Discovery, San Diego, La Jolla, CA 92093-0719, USA. brookie@ucsd.edu
Abstract
BACKGROUND: Efavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended as initial therapy. Recently, several new antiretroviral drugs, including second generation NNRTIs, protease-inhibitors, an integrase-inhibitor and a CCR5 inhibitor, have become or will be shortly available. OBJECTIVE: This article will review relevant efficacy and safety data of efavirenz compared to these novel agents or certain common alternate drugs currently used as initial therapy in treatment-naive patients. METHODS: Published articles and conference presentations pertaining to efavirenz and/or the newer antiretroviral agents were evaluated. RESULTS/ CONCLUSIONS: Efavirenz will continue to be preferred initial therapy for now. If longer-term studies of integrase inhibitors and second-generation NNRTIs confirm initial findings, they will eventually supplant efavirenz as preferred first-line agents.
BACKGROUND:Efavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended as initial therapy. Recently, several new antiretroviral drugs, including second generation NNRTIs, protease-inhibitors, an integrase-inhibitor and a CCR5 inhibitor, have become or will be shortly available. OBJECTIVE: This article will review relevant efficacy and safety data of efavirenz compared to these novel agents or certain common alternate drugs currently used as initial therapy in treatment-naive patients. METHODS: Published articles and conference presentations pertaining to efavirenz and/or the newer antiretroviral agents were evaluated. RESULTS/ CONCLUSIONS:Efavirenz will continue to be preferred initial therapy for now. If longer-term studies of integrase inhibitors and second-generation NNRTIs confirm initial findings, they will eventually supplant efavirenzas preferred first-line agents.
Authors: Saskia M E Vrouenraets; Ferdinand W N M Wit; Jacqueline van Tongeren; Joep M A Lange Journal: Expert Opin Pharmacother Date: 2007-04 Impact factor: 3.889
Authors: L T Bacheler; E D Anton; P Kudish; D Baker; J Bunville; K Krakowski; L Bolling; M Aujay; X V Wang; D Ellis; M F Becker; A L Lasut; H J George; D R Spalding; G Hollis; K Abremski Journal: Antimicrob Agents Chemother Date: 2000-09 Impact factor: 5.191
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Marc Pfister; Line Labbé; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191
Authors: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Michael B Gatch; Alexey Kozlenkov; Ren-Qi Huang; Wenjuan Yang; Jacques D Nguyen; Javier González-Maeso; Kenner C Rice; Charles P France; Glenn H Dillon; Michael J Forster; John A Schetz Journal: Neuropsychopharmacology Date: 2013-05-24 Impact factor: 7.853
Authors: Marco Siccardi; Adeniyi Olagunju; Kay Seden; Farid Ebrahimjee; Steve Rannard; David Back; Andrew Owen Journal: In Silico Pharmacol Date: 2013-03-01